Macrophage-Targeted Mms6 mRNA Nanoparticles Drive Functional Recovery After Spinal Cord Injury

Study Background and Research Question

Traumatic spinal cord injury (SCI) is a devastating condition resulting in permanent neurological deficits and disability. Despite advances in neurorestorative medicine, effective treatments remain limited, largely due to the complexity of central nervous system repair and the challenges associated with modulating the post-injury microenvironment. Recent discoveries highlight the critical role of immune cells—especially M2-type macrophages—in orchestrating repair processes by clearing debris and releasing anti-inflammatory mediators. However, leveraging these cells therapeutically has been constrained by the technical and immunological hurdles of cell transplantation. In this context, Fu et al. sought to determine whether direct, in vivo delivery of therapeutic mRNA to endogenous macrophages could enhance recovery after SCI, specifically by targeting the ferroptosis-resistant, repair-promoting Mms6 gene.

Key Innovation from the Reference Study

The central innovation in Fu et al.'s work is the design and deployment of lipid nanoparticles (LNPs) encapsulating Mms6 mRNA, modified with phosphatidylserine (PS) to preferentially target macrophages. This strategy bypasses the need for ex vivo cell manipulation or transplantation, instead exploiting the disrupted blood–spinal cord barrier post-injury to enable selective uptake by macrophages at the lesion site. The Mms6 protein, derived from magnetotactic bacteria, imparts resistance to ferroptosis—a form of iron-dependent cell death—thereby supporting macrophage survival and enhancing their reparative capacity. This approach directly addresses two key barriers in SCI therapy: targeted delivery of functional mRNA and the sustained modulation of immune cell phenotypes within the injury niche.

Methods and Experimental Design Insights

Fu et al. engineered two classes of nanoparticles: standard Mms6 mRNA-LNPs and macrophage-targeted Mms6 mRNA-PS/LNPs. The nanoparticles were administered intravenously to mice shortly after SCI induction. The study utilized a comprehensive suite of approaches, including:

• Fluorescent labeling and in situ hybridization to track mRNA delivery and expression in lesion-associated macrophages.
• Behavioral assays (such as the Basso Mouse Scale) to quantify locomotor recovery.
• Histological analyses to assess lesion volume, scar formation, neuronal survival, and axonal integrity.
• Macrophage depletion experiments to confirm cell-specific effects.

This experimental design allowed for rigorous assessment of both molecular and functional outcomes, as well as mechanistic dissection of the therapeutic effect.

Core Findings and Why They Matter

The targeted Mms6 mRNA-PS/LNPs demonstrated markedly improved uptake by macrophages at the injury site compared to untargeted LNPs. Mice receiving the targeted nanoparticles exhibited significantly better locomotor recovery, reduced lesion area, diminished scar formation, and improved neuronal and axonal preservation. Notably, these effects were abrogated when macrophages were depleted prior to treatment, confirming that the therapeutic benefit was dependent on macrophage-specific delivery and Mms6 expression. These results position macrophage-targeted mRNA therapy as a powerful, flexible tool for modulating immune cell function in situ, with broad implications for neuroregeneration and beyond. The strategy leverages the advantages of mRNA delivery for gene expression—transient, non-integrative, and tunable—while overcoming immune rejection and technical bottlenecks of cell-based therapies.

Comparison with Existing Internal Articles

This study's focus on in vivo mRNA delivery to immune cells aligns with advances in enhanced green fluorescent protein mRNA systems, such as the EZ Cap EGFP mRNA 5-moUTP platform, which emphasize stability, efficient delivery, and immune evasion. While Fu et al. deploy a therapeutic mRNA, the underlying principles of mRNA optimization (e.g., use of modified nucleotides, capping structures for translation efficiency, and immunogenicity reduction) are directly comparable. Internal articles, including scenario-based workflows (see here), reinforce the importance of robust, immune-silent mRNA formulations for reliable uptake and expression in diverse cell types. Both the reference paper and these resources underscore the critical role of delivery vehicle engineering—whether for therapeutic targets or reporter applications—in achieving desired biological outcomes and minimizing innate immune activation.

Limitations and Transferability

Despite promising results, several limitations and considerations must be acknowledged. The mouse SCI model, while highly informative, does not fully recapitulate the complexity of human injuries, and immune cell distributions and responses can differ between species. The reliance on the blood–spinal cord barrier disruption for delivery may limit translation to chronic phases or other CNS contexts. Additionally, while Mms6 mRNA delivery suppressed ferroptosis and promoted repair in macrophages, the long-term fate, safety, and potential off-target effects of repeated mRNA-PS/LNP administration remain to be fully explored. Transferability to other immune cell populations or tissue environments will require further optimization of targeting ligands and nanoparticle properties.

Protocol Parameters

• Lipid nanoparticle (LNP) formulation: Encapsulate therapeutic mRNA (e.g., Mms6) with PS modification for macrophage targeting; optimize LNP:mRNA ratio for maximal uptake and minimal off-target delivery.
• Administration: Intravenous injection shortly after SCI; timing may be critical to exploit blood–spinal cord barrier disruption.
• mRNA integrity and modification: Use capped mRNA with Cap 1 structure and modified nucleotides (e.g., 5-moUTP, as in reporter systems) to enhance translation efficiency and reduce innate immune activation.
• Macrophage depletion (for mechanistic studies): Employ clodronate liposomes or genetic models 1–2 days prior to mRNA-LNP administration to confirm cell-specific effects.
• Behavioral and histological assessment: Quantify locomotor function (BMS scoring) and lesion characteristics at weekly intervals post-treatment.

Research Support Resources

For researchers aiming to develop or validate mRNA delivery for gene expression in immune or neural contexts, robust reporter mRNAs are essential for tracking transfection efficiency, translation, and immunogenicity. EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016) is a well-characterized, immune-evasive enhanced green fluorescent protein mRNA featuring a Cap 1 structure and 5-methoxyuridine modifications, supporting translation efficiency assays and in vivo imaging with fluorescent mRNA. The product information details optimal handling, storage, and transfection protocols, and it can be incorporated into workflows paralleling those described by Fu et al. to benchmark nanoparticle-mediated mRNA delivery and expression in diverse experimental systems.